http://www.fpnotebook.com/

DihydroergotamineAka: DHE-45

Indications
1. Migraine Abortive Management
Dosing
1. Parenteral
  1. Initial: 1 mg SC/IM/IV over 3-4 minutes
  2. Repeat: May repeat every 1 hour
  3. Maximum: 3 mg/day, 6 mg/week, 20 mg/month
2. Intranasal Dihydroergotamine (Migranal)
Advantages
1. Weaker vasoconstrictor (less Side Effects)
2. No Rebound Headache
Adverse Effects
1. Retroperitoneal fibrosis

Dihydroergotamine (C0012291)
Definition (MSH)	A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.
Concepts	Organic Chemical (T109) , Pharmacologic Substance (T121)
English	Dihydroergotamine, DIHYDROERGOTAMINE PREPARATION, Dihydroergotamine product
Spanish	dihidroergotamina
Credits	Derived from the NIH UMLS (Unified Medical Language System)

Navigation Tree

Please see the Terms and Conditions. Please also see the privacy statement regarding advertising on this page. Although access to this page is not restricted, the information found here is intended for use by medical providers. Patients should address specific medical concerns with their physicians.

This page was written by Scott Moses, MD. This page was last revised before 5/10/08, prior to consistent tracking of revision date. This page was last published on 5/10/2008. Please send comments and questions to the editor. Contact information may be found on the page About the Family Practice Notebook. These pages are best viewed with Microsoft Internet Explorer 6.0.

Neurology Book

Autonomic Nervous System Disorders

Cognitive Disorders

Headache Disorders

Level of Consciousness

Miscellaneous

Motor Disorders

Obstetrics

Seizure Disorders

Tremor

http://www.fpnotebook.com/

DihydroergotamineAka: DHE-45

Dihydroergotamine (C0012291)

Navigation Tree